Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
After a tough stretch in prior years, the share price has surged 18.9% over the last week, 12.5% over the past month, and 112.3% year to date, with a 135.1% gain over the last year putting early believers well ahead of the broader market. A big part of this momentum comes from growing investor optimism around Travere's rare disease pipeline and strategic focus. The market is reassessing the long term commercial potential of its core kidney and metabolic disease franchise. At the same time, regulatory and competitive developments in the rare disease space have reminded investors that this is still a higher risk, higher reward corner of biotech. On our framework Travere scores a 3/6 valuation check score, which you can explore via our valuation summary . Next we will unpack what that means across different valuation approaches, before closing with a more practical way to think about what this stock might really be worth. Travere Therapeutics delivered 135.1% returns over the last
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday [Yahoo! Finance]Yahoo! Finance
- Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Analyst Actions
- 11/28/25 - HC Wainwright
TVTX
Sec Filings
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- 12/3/25 - Form 4
- TVTX's page on the SEC website